1.The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged Women.
Zeinab AMINILARI ; Mohammad FARAROUEI ; Sasan AMANAT ; Ehsan SINAEI ; Safa DIANATINASAB ; Mahmood AMINILARI ; Nima DANESHI ; Mostafa DIANATINASAB
Diabetes & Metabolism Journal 2017;41(3):205-212
BACKGROUND: Recent studies have shown that omentin-1 derived from adipokines can affect physiological regulations and some metabolic dis-eases such as type 2 diabetes mellitus (T2DM). METHODS: The purpose of this study was to examine the impact of 12 weeks of aerobic (cycle ergometer), resistance, and combined exercises on omentin-1 level, glucose and insulin resistance indices in overweight middle age women with T2DM. In this study, 60 overweight middle age diabetic women were selected using simple random sampling and they were assigned to three groups of aerobic exercise (n=12), resistant exercise (n=12) and combined exercise (n=13), and one control group (n=15). Exercises were done in a three times per week sessions for a total of 12 weeks. Blood samples were collected before each exercise session and 24 hours after of the last session. RESULTS: Present study showed that fasting blood sugar decreased significantly in all intervention groups, while homeostasis model assessment of insulin resistance (HOMA-IR) decreased only in the aerobic and combined exercises groups. Furthermore, there was a significant increase in the omentin-1 level only in the combined exercise group. CONCLUSION: Compared to aerobic and resistance exercises, 12 weeks of combined exercise was more efficient in improving HOMA-IR and increasing serum omentin-1 among women with T2DM.
Adipokines
;
Blood Glucose
;
Diabetes Mellitus, Type 2
;
Exercise*
;
Fasting
;
Female
;
Glucose
;
Homeostasis
;
Humans
;
Insulin Resistance*
;
Insulin*
;
Middle Aged
;
Overweight
;
Social Control, Formal
2.Corrigendum: Author's Name and Affiliation Correction: The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged Women.
Zeinab AMINILARI ; Mohammad FARAROUEI ; Sasan AMANAT ; Ehsan SINAEI ; Aria DIANATINASAB ; Mahmood AMINILARI ; Nima DANESHI ; Mostafa DIANATINASAB
Diabetes & Metabolism Journal 2017;41(5):422-422
One of the authors' names and affiliations was misprinted.
3.The quality of subgroup analyses in chronic pain randomized controlled trials: a methodological review
Mahmood AMINILARI ; Vahid ASHOORIAN ; Alexa CALDWELL ; Yasir RAHMAN ; Robby NIEUWLAAT ; Jason W. BUSSE ; Lawrence MBUAGBAW
The Korean Journal of Pain 2021;34(2):139-155
The quality of subgroup analyses (SGAs) in chronic non-cancer pain trials is uncertain. The purpose of this study was to address this issue. We conducted a comprehensive search in MEDLINE and EMBASE from January 2012 to September 2018 to identify eligible trials. Two pairs of reviewers assessed the quality of the SGAs and the credibility of subgroup claims using the 10 criteria developed by Sun et al.in 2012. The associations between the quality of the SGAs and the studies’ characteristics including risk of bias, funding sources, sample size, and the latest impact factor, were assessed using multivariable logistic regression. Our search retrieved 3,401 articles of which 66 were eligible. The total number of SGAs was 177 of which 52 (29.4%) made a subgroup claim. Of these, only 15 (8.5%) were evaluated as being of high quality. Among the 30 SGAs that claimed subgroup effects using an appropriate method of performing interaction tests, the credibility of only 5 were assessed as high. None of the subgroup claims met all the credibility criteria.No significant association was found between the quality of SGAs and the studies’ characteristics. The quality of the SGAs performed in chronic pain trials was poor.To enhance the quality of SGAs, scholars should consider the developed criteria when designing and conducting trials, particularly those which need to be specified a priori.
4.The quality of subgroup analyses in chronic pain randomized controlled trials: a methodological review
Mahmood AMINILARI ; Vahid ASHOORIAN ; Alexa CALDWELL ; Yasir RAHMAN ; Robby NIEUWLAAT ; Jason W. BUSSE ; Lawrence MBUAGBAW
The Korean Journal of Pain 2021;34(2):139-155
The quality of subgroup analyses (SGAs) in chronic non-cancer pain trials is uncertain. The purpose of this study was to address this issue. We conducted a comprehensive search in MEDLINE and EMBASE from January 2012 to September 2018 to identify eligible trials. Two pairs of reviewers assessed the quality of the SGAs and the credibility of subgroup claims using the 10 criteria developed by Sun et al.in 2012. The associations between the quality of the SGAs and the studies’ characteristics including risk of bias, funding sources, sample size, and the latest impact factor, were assessed using multivariable logistic regression. Our search retrieved 3,401 articles of which 66 were eligible. The total number of SGAs was 177 of which 52 (29.4%) made a subgroup claim. Of these, only 15 (8.5%) were evaluated as being of high quality. Among the 30 SGAs that claimed subgroup effects using an appropriate method of performing interaction tests, the credibility of only 5 were assessed as high. None of the subgroup claims met all the credibility criteria.No significant association was found between the quality of SGAs and the studies’ characteristics. The quality of the SGAs performed in chronic pain trials was poor.To enhance the quality of SGAs, scholars should consider the developed criteria when designing and conducting trials, particularly those which need to be specified a priori.